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complementary and alternative medicine (CAM) in patients with inborn errors
of metabolism (IEM). This study's objective was to evaluate the self-reported
use and perceived effectiveness of CAM in adults and children with IEM.
Methods: Patients aged 0-70 years and caregivers seen at the London Health
Sciences Centre Metabolic Clinic (London, Ontario, Canada) between July 2017
and August 2017 were recruited to complete a questionnaire regarding CAM
use to help their IEM diagnosis and perceived effectiveness of these therapies.
Survey responses were analyzed using descriptive statistics; age, sex, and education level associations among CAM users were tested using the Pearson χ 2 test.
Results: Of 50 potential participants, 44 (88%) completed the questionnaire,
including 21 adults (6 by caregivers) and 23 children (22 by caregivers). The
most common IEM category was Aminoacidopathies and Small Molecule Disorders (50%). Twenty-seven (61%) participants reported CAM use to help their
IEM diagnosis. The most common CAM therapies used were chiropractic
manipulation, omega-3 fatty acids, probiotics, and aromatherapy/essential oils.
Most CAM users and caregivers (74%) perceived their CAM therapies as effective overall. Among CAM users, 40% had not discussed CAM use with a health
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care professional (HCP). CAM use was similar when comparing age, sex and
education level.
Conclusions: CAM is commonly used among patients with IEM. The safety
and efficacy of CAM therapies for IEM should be further investigated. HCPs
and patients should openly discuss CAM use in order to evaluate safety.
KEYWORDS
complementary and alternative medicine, complementary therapies, inborn errors of
metabolism, integrative medicine, surveys and questionnaires
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1 | INTRODUCTION

2 | METHODS

Complementary and alternative medicine (CAM) is
defined by the National Center for Complementary and
Integrative Health (NCCIH) as “a group of diverse medical and health care systems, practices, and products that
are not generally considered part of conventional medicine”.1 CAM therapies include, but are not limited to,
natural products (eg, herbal supplements, probiotics),
mind and body practices (eg, chiropractic manipulation,
yoga, meditation), and other health approaches (eg, Traditional Chinese Medicine, naturopathy).2 There is a high
prevalence of CAM use in North America with 79% of
Canadians in 2016 reporting having tried CAM in their
lifetime.3,4 Additionally, many caregivers find CAM beneficial and prefer it over conventional medicine for their
children.5 However, it is often overlooked that CAM may
lead to adverse events.6-8
There remains a paucity of information on the use
and effectiveness of CAM in patients with inborn errors
of metabolism (IEM), a group of over 500 disorders that
affects approximately 50.9 in 100 000 live births globally.9 Since IEM are individually rare, conventional
treatments are limited for many disorders; therefore,
many patients with IEM may use CAM to treat symptoms and improve their quality of life. Recent CAM use
estimates include 41% of patients with IEM in Turkey,10
and nearly half of patients with lysosomal storage diseases in the United States.11 Additionally, recent studies
have investigated the effects of individual CAM therapies on specific IEM disorders, such as acupuncture in
patients with Gaucher disease.12 However, less than
15% of CAM users with IEM have reported discussing
their CAM use with their physician.10 Many IEM disorders present with significant systemic manifestations
and are treated with physician-prescribed dietary therapy. Use of certain CAM therapies in patients with IEM
may be of particular concern as some CAM therapies
have been associated with life-threatening adverse
effects such as organ toxicities and mechanical injuries.13-15 Therefore, it is important for physicians and
allied health professionals to be aware of the prevalence
of CAM use, and openly discuss CAM use with their
patients with IEM in order to evaluate safety and possible adverse interactions.
This study aimed to investigate the self-reported use
and perceived effectiveness of CAM in adults and children with IEM, and the factors associated with using
these therapies. This study also provides preliminary
information of CAM use and perceived effectiveness in
patients with IEM in Canada.

A cross-sectional questionnaire study was conducted
on adult and pediatric patients with IEM aged 0 to
70 years who attended their London Health Sciences
Centre (LHSC) Metabolic Clinic appointment in
London, Ontario, Canada, between July 2017 and
August 2017. The questionnaire (Supplementary
Material S1) was developed de novo after reviewing
similar surveys11,16-18 and included questions
regarding the patient's age, sex, ethnicity, education
level, IEM diagnosis, and experiences with CAM.
Caregivers present at the appointment completed
the questionnaire for patients who were unable to
independently do so, and their education level was
also obtained. IEM diagnoses were organized into
categories for patient data privacy and statistical
purposes.
Participants were asked about past and present
use of 15 CAM supplements and 21 CAM treatments/practices to help their IEM diagnosis, which
were selected based on previous relevant studies and
clinical experience (Supplementary Material S1). Participants also had the option to include unlisted
CAM therapies that they have used. A participant
was classified as a “CAM User” if they reported use
of at least one CAM therapy to help their IEM diagnosis. CAM Users were then asked to report their
perceived effectiveness for each used CAM therapy
using a Likert scale of 0-5, with 0 being “not effective at all”, and 5 being “very effective.” A CAM
therapy was classified as “perceived effective” if it
received a median score of 3 or above on the Likert
scale. If a CAM User received a mean score of 3 or
above for all their used CAM therapies, their individual CAM use was considered as “perceived effective”
overall. The questionnaire also included questions
about whether CAM Users had discussed their CAM
use with a health care professional (HCP) and associated financial costs.
The questionnaire data were collected using Microsoft
Excel and analyzed using SPSS version 24 (IBM Corp.,
Armonk, New York). Descriptive statistics were obtained
to examine demographic and disease characteristics, as
well as prevalence and perceptions of CAM use. Pearson
χ 2 tests were used to determine age, sex and education
level associations among CAM Users; P < .05 was considered statistically significant. This study was approved by
the Western University Research Ethics Board and Lawson Health Research Institute (London, Ontario,
Canada).
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3 | R E SUL T S
3.1 | Study population
During the study period, 50 patients were approached to
complete the questionnaire, and 44 (88%) agreed to participate. The demographic and diagnosis characteristics
of the study population are described in Table 1. A total
of 52% of participants were children aged 0-17 years and
52% of participants were male. The questionnaire was
completed by caregivers for 29% and 96% of our adult
TABLE 1

and pediatric participants respectively. Twenty-four IEM
disorders were represented in the study's cohort. The
most common reported IEM diagnosis category was Aminoacidopathies and Small Molecule disorders (50%), and
Phenylketonuria was the most common diagnosis (20%).
The majority of participants were Caucasian (91%), and
most individuals who completed the questionnaire (ie,
patients who independently completed the questionnaire
and caregivers who completed the questionnaire on the
patient's behalf) had some postsecondary education or
higher (66%).

Demographic characteristics, diagnosis distribution and CAM use of participants
All
participants (N = 44)

Children
(0-17 years) (N = 23)

28 (64%)

22 (96%)

6 (29%)

Male

23 (52%)

13 (57%)

10 (48%)

Female

21 (48%)

10 (43%)

11 (52%)

22 (50%)

15 (65%)

7 (33%)

Energy disorders and Mitochondrial
disordersb

8 (18%)

4 (17%)

4 (19%)

Lysosomal storage disordersc

5 (11%)

2 (9%)

3 (14%)

3 (7%)

1 (4%)

2 (10%)

6 (14%)

1 (4%)

5 (24%)

40 (91%)

20 (87%)

20 (95%)

South East Asian

1 (2%)

1 (4%)

0 (0%)

Aboriginal

1 (2%)

1 (4%)

0 (0%)

2 (5%)

1 (4%)

1 (5%)

Questionnaire completed by caregiver, n
(%)

Adults
(18-70 years) (N = 21)

Sex, n (%)

IEM diagnosis, n (%)
Aminoacidopathies and Small Molecule
disordersa

d

Carbohydrate disorders
Miscellaneous

e

Ethnicity, n (%)
Caucasian

Other

f

Education level of questionnaire completer, n (%)
High school diploma or less

15 (34%)

8 (35%)

7 (33%)

Some postsecondary education or higher

29 (66%)

15 (65%)

14 (67%)

Yes

27 (61%)

13 (57%)

14 (67%)

No

17 (39%)

10 (43%)

8 (38%)

Use of CAM, n (%)

Note: No participants reported the following ethnicities: Arab, Black, Chinese, Latin American, South Asian.
Abbreviations: CAM, complementary and alternative medicine; IEM, inborn errors of metabolism.
a
Aminoacidopathies and Small Molecule disorders include Arginase deficiency, Argininosuccinate lyase (ASL) deficiency, Biotinidase deficiency, Glucose
transporter 1 (GLUT1) deficiency, Methylenetetrahydrofolate reductase (MTHFR) deficiency, Methylmalonic acidemia, Ornithine transcarbamylase (OTC)
deficiency (including carriers), Phenylketonuria (PKU), and Pyridoxine-dependent epilepsy (PDE).
b
Energy disorders and Mitochondrial disorders include Medium-chain acyl-CoA dehydrogenase deficiency (MCADD), Mitochondrial encephalomyopathy,
lactic acidosis, and stroke-like episodes (MELAS), Mitochondrial disease, and Mitochondrial myopathy.
c
Lysosomal storage disorders include Fabry, Gaucher, Lysosomal acid lipase deficiency (LAL-D), Mucopolysaccharidosis type IVA (MPS IVA), and Pompe.
d
Carbohydrate disorders include Classic galactosemia, and Glycogen storage disease type 1A.
e
Miscellaneous disorders include Acute intermittent porphyria (AIP), Congenital disorder of glycosylation type 1A (CDG1A), Growth hormone deficiency and
Developmental delay, and Smith-Lemli-Opitz syndrome.
f
Other ethnicities reported include multi-ethnic, or participant did not disclose.
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3.2 | Use of CAM
Twenty-seven (61%) of the 44 participants reported CAM
use to help their IEM diagnosis. Of the 27 CAM Users,
13 (48%) were children and 14 (52%) were adults
(Table 1). Table 2 describes the characteristics of CAM
use by our CAM Users. The most frequently reported reasons for using CAM included “To relieve symptoms”
(76%, N = 17), “To complement my prescribed medical
therapy” (41%, N = 17), and “To try something
new/different” (35%, N = 17) (Table 2). An average of
four different CAM therapies was used among CAM
Users. The most commonly used CAM supplements were
omega-3 fatty acids (37%), probiotics (37%), and megavitamin therapy (22%), and the most commonly used CAM
treatments/practices were chiropractic manipulation
(41%) and aromatherapy/essential oils (30%) (Table 3).
Eight (40%, N = 20) CAM Users claimed that they had
not discussed their CAM use with a conventional HCP
such as physicians, dieticians, nurses, or pharmacists; the
majority of these respondents were adults (63%, N = 8)

TABLE 2

(Table 2). CAM Users most frequently reported spending
$0-$100 CAD per month on CAM (75%, N = 16)
(Table 2). Among CAM Users, there were no significant
differences between CAM use and age (children vs
adults, P = .490), sex (males vs females, P = .490), or education level of the questionnaire completer (high school
diploma or less vs some postsecondary education or
higher, P = .603).

3.3 | Perceived effectiveness of CAM
therapies
Most CAM Users and caregivers (74%) perceived their
own CAM therapies as effective in helping with their IEM
diagnosis and associated symptoms. Of the 15 CAM supplements listed in the questionnaire, 8 received a median
Likert scale score of 3 or above, and were therefore considered as “perceived effective”: garlic supplements, megavitamin therapy, probiotics, echinacea, fenugreek, flaxseed,
omega-3 fatty acids, and prebiotics (Table 3). Antioxidants,

Characteristics of CAM use
All CAM
Users (N = 27)

Reasons for using CAM, n (%)
To relieve symptoms

(N = 17)

Children
(0-17 years) (N = 13)
(N = 9)

Adults
(18-70 years) (N = 14)
(N = 8)

13 (76%)

6 (67%)

6 (75%)

To complement my prescribed medical
therapy

7 (41%)

4 (44%)

3 (38%)

To try something new/different

6 (35%)

3 (33%)

3 (38%)

My CAM therapies make me feel better

4 (24%)

1 (11%)

3 (38%)

Not satisfied with my prescribed medical
therapy

4 (24%)

3 (33%)

1 (13%)

Suggested by a conventional medical
professional

3 (18%)

0 (0%)

3 (38%)

Discussed CAM use with a HCP, n (%)

(N = 20)

(N = 11)

(N = 9)

Yes

12 (60%)

8 (73%)

4 (44%)

No

8 (40%)

3 (27%)

5 (56%)

HCPs that participants have discussed CAM
use with, n (%)

(N = 12)

(N = 8)

(N = 4)

Physician

8 (67%)

4 (50%)

4 (100%)

Dietician

5 (42%)

5 (63%)

0 (0%)

Physiotherapist

4 (33%)

2 (25%)

2 (50%)

Cost of CAM per month, n (%)
$0-100 CAD
$100-400 CAD

(N = 16)

(N = 9)

(N = 7)

12 (75%)

6 (67%)

6 (86%)

4 (25%)

3 (33%)

1 (14%)

Notes: No participants reported using CAM “to combat the prescribed medical therapy's side effect(s),” “because prescribed medical therapy is too expensive.”
No participants reported discussing CAM use with a genetic counselor, nurse practitioner, pharmacist, registered nurse, other HCP.
Abbreviations: CAD, Canadian dollar; CAM, complementary and alternative medicine; HCP, health care professional.

TAO ET AL.

109

TABLE 3

Most common CAM supplements and treatments/practices used by patients with IEM

CAM therapy

All CAM Users,
n (%) (N = 27)

Median perceived
effectivenessa (IQR)

Children (0-17 years),
n (%) (N = 13)

Adults (18-70 years),
n (%) (N = 14)

Supplements
Antioxidants

3 (11%)

2 (1.5-3.5)

2 (15%)

1 (7%)

Echinacea

4 (15%)

3 (2.25-3)

0 (0%)

4 (29%)

Fenugreek

1 (4%)

3 (3-3)

0 (0%)

1 (7%)

Flaxseed

5 (19%)

3 (3-4)

3 (23%)

2 (14%)

Garlic
supplements

4 (15%)

4 (4-4.25)

3 (23%)

1 (7%)

Ginseng

2 (7%)

2 (1-3)

0 (0%)

2 (14%)

Glucosamine
(only)

2 (7%)

0 (0-0, n = 1)

1 (8%)

1 (7%)

Megavitamin
therapy

6 (22%)

4 (3.25-4)

3 (23%)

3 (21%)

Omega-3 fatty
acids

10 (37%)

3 (2-3.75)

7 (54%)

3 (21%)

3 (3-3)

1 (8%)

0 (0%)

5 (38%)

5 (36%)

2 (2-2, n = 5)

3 (23%)

1 (7%)

4 (4-4)

0 (0%)

1 (7%)

0 (0%)

2 (14%)

3 (23%)

5 (36%)

Prebiotics

1 (4%)

Probiotics

10 (37%)

Other

b

4 (15%)

3.5 (3-5)

Treatments/
practices
Acupressure

1 (4%)

Acupuncture

2 (7%)

Aromatherapy/
essential oils

8 (30%)

Chiropractic

11 (41%)

4 (3.5-5)

4 (31%)

7 (50%)

Energy healing/
Reiki

2 (7%)

3 (3-3)

1 (8%)

1 (7%)

Guided imagery

2 (7%)

4 (3.5-4.5)

0 (0%)

2 (14%)

Massage therapy

4 (15%)

Meditation

4 (15%)

Naturopathy

2 (7%)

Reflexology

3.5 (3.25-3.75)
4 (4-4)

1 (8%)

3 (21%)

0 (0%)

4 (29%)

3 (2.5-3.5)

2 (15%)

0 (0%)

1 (4%)

3 (3-3)

1 (8%)

0 (0%)

Spiritual healing
by others

4 (15%)

4 (3.25-4.25)

0 (0%)

4 (29%)

Water therapy

4 (15%)

4 (3.75-4.25)

2 (15%)

2 (14%)

Yoga

3 (11%)

3 (3-3.5)

0 (0%)

3 (21%)

5 (19%)

5 (4-5, n = 7)

2 (15%)

3 (21%)

Other

c

5 (4.75-5)
4.5 (3.5-5)

Notes: No participants reported use of genistein, ginkgo, glucosamine + chondroitin, MSM. No participants reported use of Ayurveda, biofeedback, cupping
therapy, homeopathy, magnetic therapy, osteopathy, progressive relaxation, and Traditional Chinese Medicine.
Abbreviations: CAM, complementary and alternative medicine; IEM, inborn errors of metabolism; IQR, interquartile range (first–third quartile); MCT,
medium-chain triglyceride; MSM, methylsulfonylmethane.
a
Likert scale from 0 to 5.
b
Other CAM supplements used by participants include cannabis/hemp oil, digestive enzymes, dragon fruit, ginger, MCT oil. Participants were allowed to
report use of more than one “Other” CAM supplement.
c
Other CAM treatments/practices used by participants include music therapy, physical activity, REID diet, and self-help groups. Participants were allowed to
report use of more than one “Other” CAM treatment/practice.
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ginseng, and glucosamine were not perceived as effective
by CAM Users (Table 3). Additionally, all 14 CAM treatments/practices listed in the questionnaire that CAM
Users reported using were considered as “perceived effective”: massage therapy, meditation, acupressure, aromatherapy/essential oils, chiropractic manipulation, guided
imagery, spiritual healing by others, water therapy, acupuncture, energy healing/reiki, naturopathy, reflexology,
and yoga (Table 3).

4 | DISCUSSION
This study describes CAM use in adults and children
with IEM aged 0-70 years from a Canadian metabolic
center, perceived effectiveness of over 20 CAM therapies, and factors associated with using these therapies.
Following a high response rate (88%), our study found a
61% prevalence of CAM use in patients with IEM. This
was a higher prevalence than in studies by Erdol and
Saglam (41.1%) and Balwani et al (40%, 42%, and 41%
for patients with Type 1 Gaucher disease, Fabry disease,
and Type B Niemann-Pick disease, respectively). This
was also higher than overall CAM use in the United
States (33.2% of adults, 11.6% of children)17,18 and
Europe (25.9%),19 but lower than Canadian estimates
(79% of adults, 62% of children).3,20 This variability in
CAM use prevalence may be due to differences in
acceptability, accessibility, cost, and insurance coverage
of CAM in different countries, as well as inconsistencies
in the classification of CAM. Nonetheless, our study provides further evidence supporting the high use of CAM
in patients with IEM.
Participants most commonly used CAM to relieve
symptoms and complement their prescribed medical
therapy. This is consistent with similar studies, as most
patients use CAM together with their prescribed conventional therapy and not in place of, which is also known
as integrative medicine.2,21,22 However, about one-fourth
of participants reported using CAM because they were
not satisfied with their conventional medical therapy, or
lack thereof. Studies have shown that patients may use
CAM because they gradually lose confidence or satisfaction in conventional care for chronic diseases.23,24 CAM
use was also higher in patients with an untreatable IEM
disorder,10 which includes disorders with limited conventional therapy options. Despite the use of CAM, it is
important that IEM patients do not stop their conventional therapy when it is available, especially for IEM disorders that can lead to toxic metabolites (eg, PKU,
MCADD, Galactosemia) or energy deficiencies (eg,
MCADD, Mitochondrial disorders).
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The most commonly used CAM therapies were chiropractic manipulation, omega-3 fatty acids, probiotics, aromatherapy/essential oils, megavitamin therapy, and
flaxseed. This is consistent with fish oil (rich in omega-3
fatty acids) being the most commonly used natural product in the United States,17,18 and chiropractic manipulation being popular in Canada and the United States.3,17,18
High use of flaxseed, omega-3 fatty acids, and megavitamin therapy was also reported in patients with lysosomal
storage diseases.11 High use of these therapies may be
due to their accessibility, affordability, higher prevalence
in the media, and recommendations from family and friends. Megavitamin therapy is also known to be recommended by physicians for mitochondrial disorders.
The relatively low spending on CAM ($100 CAD or less
per month) may be attributable to the universal
healthcare system and private health insurance options
that cover CAM therapies in Canada.
Participants who used CAM were found to have no
significant differences in age, sex, or education level. Previous studies have demonstrated increased CAM use in
females, adults, and those with higher education when
compared to CAM Non-users.11,21,22 Comparisons
between CAM Users and CAM Non-users were not performed due to our limited sample size, therefore making
the study underpowered to adequately analyze these
comparisons. These comparisons are warranted in future
studies.
Overall, the CAM Users of this study viewed CAM
favorably and found their CAM therapies effective. Due
to the various manifestations and symptoms that may
present in different IEM disorders, it is difficult to generalize the effectiveness of CAM therapies for all patients
with IEM. Additionally, with the rise of integrative health
and evidence-based medicine, certain CAM therapies
may not be considered CAM for certain IEMs. More controlled studies should be performed to further understand
the effectiveness of CAM therapies in patients with IEM.
A total of 40% of participants had not discussed their
CAM use with a conventional HCP. This finding is
higher than in the study by Balwani et al, but lower than
Erdol and Saglam; these differences may be due to variations in acceptance and awareness towards CAM in different cultures. Of those who had discussed their CAM
use, one-third had not discussed it with their physician.
Additionally, no adults had discussed their CAM use with
a dietician, a HCP who plays a significant role in the care
of many patients with IEM. It is likely that some patients
decide to use CAM based on the Internet or personal
anecdotes. A lack of consistent communication between
patients and HCPs could lead to preventable adverse
events and drug interactions. For example, harm from
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chiropractic manipulation has been reported in children
with underlying medical pathology25; patients with IEM
who have osteopenia or osteoporosis are at particular
risk. Large doses of omega-3 fatty acids may decrease
platelet aggregation and, thus, increase bleeding time;
this may be harmful in glycogen storage diseases that are
associated with platelet function defects.26 Some herbal
therapies have also been associated with various renal
syndromes.13 Nonetheless, all HCPs are encouraged to
provide an open and judgment-free environment to discuss CAM in order to provide safe and patient-centered
care to patients with IEM.

4.1 | Limitations
Our sample size was smaller than other similar studies,
thereby impacting our study's external validity and
power. Selection bias was possible as we had a distribution of IEM disorders that may not be representative of
this patient population. There may also be recall bias due
to the nature of the questionnaire questions. Lastly, as an
exploratory study, we were unable to provide conclusive
evidence on the effectiveness of CAM therapies for
patients with IEM. However, our findings should encourage larger, controlled trials on the safety and efficacy of
CAM in patients with IEM to be performed.

5 | C ON C L U S I ON
CAM is commonly used in patients with IEM. Overall,
patients with IEM and caregivers view their CAM therapies as effective; however, many patients are not informing their physicians and allied health care team about
their CAM use. Therefore, HCPs are encouraged to stay
informed about CAM, openly discuss CAM use with their
patients in order to evaluate safety, and advocate for the
development of further research in this area.
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